Genesis Therapeutics uses artificial intelligence to speed up drug discovery for the pharmaceutical industry. Its platform combines 3D spatial graph modeling with advanced molecular simulation to generate potential drug candidates and to explore new chemical spaces and protein targets. They operate on a business-to-business model, partnering with biotech and pharma companies and earning upfront payments and milestones from collaborations (for example, a Lilly deal worth up to $670 million). Their goal is to deliver AI-generated drug ideas and validated leads to collaborators, accelerating the path from target to therapeutic candidate.
Company Size
51-200
Company Stage
Late Stage VC
Total Funding
$400.1M
Headquarters
San Mateo, CA
Founded
2019
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?